Shares Outstanding Shares Outstanding n/a Close	22.2M
Shares Change (YoY) Shares Change (YoY) n/a Close	3.61%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	1.24%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	99.99%
Shares Floating Shares Floating n/a Close	20.08M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	16,047
FTD / Avg. Volume FTD / Avg. Volume n/a Close	4.89%

Short Selling Information

The latest short interest is 3.89M, so 17.5% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	3.89M
Short % of Shares Out Short % of Shares Out n/a Close	17.5%
Short % of Float Short % of Float n/a Close	20.29%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	12.08

Valuation Ratios

The PE ratio is -14.09 and the forward PE ratio is -284.44. Madrigal Pharmaceuticals's PEG ratio is -1.47.

PE Ratio PE Ratio n/a Close	-14.09
Forward PE Forward PE n/a Close	-284.44
PS Ratio PS Ratio n/a Close	36.44
Forward PS Forward PS n/a Close	1.7
PB Ratio PB Ratio n/a Close	8.7
P/FCF Ratio P/FCF Ratio n/a Close	-14.36
PEG Ratio PEG Ratio n/a Close	-1.47

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Madrigal Pharmaceuticals.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 6.1, with a Debt / Equity ratio of 0.16.

Current Ratio Current Ratio n/a Close	6.1
Quick Ratio Quick Ratio n/a Close	5.9
Debt / Equity Debt / Equity n/a Close	0.16
Debt / EBITDA Debt / EBITDA n/a Close	-0.27
Debt / FCF Debt / FCF n/a Close	-0.26
Interest Coverage Interest Coverage n/a Close	-33.94

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$341,160.98
Profits Per Employee Profits Per Employee n/a Close	$-882,371.21
Employee Count Employee Count n/a Close	528
Asset Turnover Asset Turnover n/a Close	0.17
Inventory Turnover Inventory Turnover n/a Close	0.18

Taxes

Income Tax Income Tax n/a Close	n/a
Effective Tax Rate Effective Tax Rate n/a Close	0%

Stock Price Statistics

The stock price has increased by 2.98% in the last 52 weeks. The beta is -1.08, so Madrigal Pharmaceuticals's price volatility has been lower than the market average.

Beta Beta n/a Close	-1.08
52-Week Price Change 52-Week Price Change n/a Close	2.98%
50-Day Moving Average 50-Day Moving Average n/a Close	297.81
200-Day Moving Average 200-Day Moving Average n/a Close	294.87
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	47.76
Average Volume (20 Days) Average Volume (20 Days) n/a Close	328,171

Income Statement

In the last 12 months, Madrigal Pharmaceuticals had revenue of 180.13M and earned -465.89M in profits. Earnings per share was -21.9.

Revenue Revenue n/a Close	180.13M
Gross Profit Gross Profit n/a Close	173.9M
Operating Income Operating Income n/a Close	-497.88M
Net Income Net Income n/a Close	-465.89M
EBITDA EBITDA n/a Close	-450.13M
EBIT EBIT n/a Close	-451.22M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-21.9

Full Income Statement

Balance Sheet

The company has 100.02M in cash and 119.57M in debt, giving a net cash position of -19.55M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	100.02M
Total Debt Total Debt n/a Close	119.57M
Net Cash Net Cash n/a Close	-19.55M
Retained Earnings Retained Earnings n/a Close	-1.8B
Total Assets Total Assets n/a Close	996.63M
Working Capital Working Capital n/a Close	820.74M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -455.57M and capital expenditures -1.46M, giving a free cash flow of -457.03M.

Operating Cash Flow Operating Cash Flow n/a Close	-455.57M
Capital Expenditures Capital Expenditures n/a Close	-1.46M
Free Cash Flow Free Cash Flow n/a Close	-457.03M
FCF Per Share FCF Per Share n/a Close	-21.48

Full Cash Flow Statement

Margins

Gross margin is 96.54%, with operating and profit margins of -276.39% and -258.64%.

Gross Margin Gross Margin n/a Close	96.54%
Operating Margin Operating Margin n/a Close	-276.39%
Pretax Margin Pretax Margin n/a Close	-258.64%
Profit Margin Profit Margin n/a Close	-258.64%
EBITDA Margin EBITDA Margin n/a Close	-249.88%
EBIT Margin EBIT Margin n/a Close	-276.39%
FCF Margin FCF Margin n/a Close	-253.72%

Dividends & Yields

MDGL does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for MDGL is $431.5, which is 51.4% higher than the current price. The consensus rating is "Strong Buy".

Price Target Price Target n/a Close	$431.5
Price Target Difference Price Target Difference n/a Close	51.4%
Analyst Consensus Analyst Consensus n/a Close	Strong Buy
Analyst Count Analyst Count n/a Close	9

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Jul 25, 2016. It was a backward split with a ratio of 1:35.

Last Split Date Last Split Date n/a Close	Jul 25, 2016
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:35

Scores

Altman Z-Score Altman Z-Score n/a Close	9.96
Piotroski F-Score Piotroski F-Score n/a Close	3